Cargando…

Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China

PURPOSE: To compare short-term anatomical outcomes observed in optical coherence tomography (OCT) between intravitreal injection (IVI) with anti-vascular endothelial growth factor (VEGF) agent aflibercept (IVA) and subthreshold micropulse laser (SML) therapy in chronic central serous chorioretinopat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Tantai, Li, Jiani, Wang, Yanbin, Guo, Xiaojian, Sun, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Ophthalmology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312034/ https://www.ncbi.nlm.nih.gov/pubmed/37382371 http://dx.doi.org/10.1080/07853890.2023.2227424

Ejemplares similares

Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy
por: Abd Elhamid, Ahmed Hosni
Publicado: (2015)

Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy
por: Maruko, Ichiro, et al.
Publicado: (2017)

Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis
por: Ramirez Marquez, Estefania, et al.
Publicado: (2022)

OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy
por: Zheng, Fang, et al.
Publicado: (2022)

Commentary: Subthreshold micropulse yellow laser for central serous chorioretinopathy: Finding the right protocol
por: Saurabh, Kumar, et al.
Publicado: (2022)

Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser
por: Gawęcki, Maciej, et al.
Publicado: (2017)

Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy
por: Sun, Zuhua, et al.
Publicado: (2019)

Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
por: Zeng, Miao, et al.
Publicado: (2022)

577 nm subthreshold micropulse laser treatment for acute central serous chorioretinopathy: a comparative study
por: Long, He, et al.
Publicado: (2022)

Comparison of two protocols of subthreshold micropulse yellow laser treatment for non-resolving central serous chorioretinopathy
por: Beniwal, Abhijeet, et al.
Publicado: (2022)

Functional Outcomes and Safety Profile of Trans-Foveal Subthreshold Micropulse Laser in Persistent Central Serous Chorioretinopathy
por: Kiraly, Peter, et al.
Publicado: (2023)

Increase in Central Retinal Edema after Subthreshold Diode Micropulse Laser Treatment of Chronic Central Serous Chorioretinopathy
por: Gawęcki, Maciej
Publicado: (2015)

Role of 532 nm transfoveal subthreshold micropulse laser in non-resolving central serous chorioretinopathy with subfoveal leaks
por: Ambiya, Vikas, et al.
Publicado: (2020)

Subthreshold Micropulse Laser vs. Conventional Laser for Central Serous Chorioretinopathy: A Randomized Controlled Clinical Trial
por: Zhou, Lijun, et al.
Publicado: (2021)

Interobserver Agreement of Novel Classification of Central Serous Chorioretinopathy
por: Sahoo, Niroj K, et al.
Publicado: (2022)

Low-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the Treatment of Chronic Central Serous Chorioretinopathy
por: Özmert, Emin, et al.
Publicado: (2016)

Comparison of the efficacy and safety of subthreshold micropulse laser with photodynamic therapy for the treatment of chronic central serous chorioretinopathy: A meta-analysis
por: Wu, Zhizhong, et al.
Publicado: (2021)

Central serous chorioretinopathy in primary hyperaldosteronism
por: van Dijk, Elon H. C., et al.
Publicado: (2016)

Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
por: Karim, Shaheen P, et al.
Publicado: (2013)

Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection
por: Sharifi, Ali, et al.
Publicado: (2022)

Submacular Hemorrhage Following Aflibercept Intravitreal Injection: A Report of Two Cases
por: Khoo, Chloe, et al.
Publicado: (2022)

Retinal Imaging and Optical Coherence Tomography of Choroidal Haemangioma Mimicking Central Serous Chorioretinopathy
por: Jugnarain, Davina, et al.
Publicado: (2023)

Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy
por: Vyas, Chinmayi Himanshuroy, et al.
Publicado: (2021)

532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy
por: Sousa, Keissy, et al.
Publicado: (2020)

Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Noh, Sung Rae, et al.
Publicado: (2019)

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane
por: Radke, Nishant, et al.
Publicado: (2017)

Bilateral and Multiple Central Serous Chorioretinopathy Following COVID-19 Infection: A Case Report and Literature Review
por: Mohd-Alif, W Mohd, et al.
Publicado: (2022)

Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study
por: Marques, João Pedro, et al.
Publicado: (2017)

Occlusion of a Vortex Vein After Treatment With Half-Fluence Photodynamic Therapy Combined With Intravitreal Aflibercept Injection for Pachychoroid Neovasculopathy
por: Yamada, Chizu, et al.
Publicado: (2022)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy
por: Iacono, Pierluigi, et al.
Publicado: (2020)

Comparison of oral propranolol, oral rifampicin, and intravitreal anti-VEGF in central serous chorioretinopathy
por: Sandeep, K, et al.
Publicado: (2023)

Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

An Uncommon Aflibercept Side Effect: Full Thickness Macular Hole Formation After Intravitreal Injections in Patients With Pre-existing Vitreomacular Traction
por: Karamitsos, Athanasios, et al.
Publicado: (2021)

Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy
por: Ünlü, Cihan, et al.
Publicado: (2016)

The Effect of Intravitreal Bevacizumab on Central Serous Chorioretinopathy
por: Maleki, Alireza, et al.
Publicado: (2018)

The Uses of Photodynamic Therapy Versus Anti-vascular Endothelial Growth Factor in the Management of Acute Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis
por: Seraj, Hadeel, et al.
Publicado: (2023)

Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset
por: Gawęcki, Maciej, et al.
Publicado: (2019)

Morphometric analyses in patients treated with subthreshold laser photocoagulation for central serous chorioretinopathy
por: Enders, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ab2u6ge37umanlj242judtho6